Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) FCF Margin (2018 - 2026)

Sunshine Biopharma filings provide 9 years of FCF Margin readings, the most recent being 18.83% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 1773.0% to 18.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 15.16%, a 2550.0% increase, with the full-year FY2025 number at 15.16%, up 2550.0% from a year prior.
  • FCF Margin hit 18.83% in Q4 2025 for Sunshine Biopharma, down from 7.81% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 7.81% in Q3 2025 to a low of 1192.65% in Q3 2021.
  • Median FCF Margin over the past 5 years was 51.38% (2024), compared with a mean of 309.58%.
  • The widest YoY moves for FCF Margin: up 114713bps in 2021, down -62889bps in 2021.
  • Sunshine Biopharma's FCF Margin stood at 366.68% in 2021, then skyrocketed by 83bps to 61.95% in 2022, then soared by 52bps to 30.04% in 2023, then fell by -22bps to 36.56% in 2024, then skyrocketed by 48bps to 18.83% in 2025.
  • The last three reported values for FCF Margin were 18.83% (Q4 2025), 7.81% (Q3 2025), and 15.23% (Q2 2025) per Business Quant data.